Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine–lenalidomide combination the way to go?

References

• Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6), 2079–2088 (1997).
   PubMed Web of Science ®Google Scholar
• Giagounidis AA, Germing U, Aul C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin. Cancer Res. 12(1), 5–10 (2006).
   PubMed Web of Science ®Google Scholar
• Boultwood J, Fidler C, Lewis S et al. Molecular mapping of uncharacteristically small 5q deletions in two patients with the 5q- syndrome: delineation of the critical region on 5q and identification of a 5q- breakpoint. Genomics 19(3), 425–432 (1994).
   PubMed Web of Science ®Google Scholar
• Willman CL, Sever CE, Pallavicini MG et al. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 259(5097), 968–971 (1993).
   PubMed Web of Science ®Google Scholar
• Zeidan A, Faltas B, Smith BD et al. Myelodysplastic syndromes: what do hospitalists need to know? J. Hosp. Med. (2013) (In Press).
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al.; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, Phase III study. Lancet Oncol. 10(3), 223–232 (2009).
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 20(10), 2429–2440 (2002).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a Phase III randomized study. Cancer 106(8), 1794–1803 (2006).
   PubMed Web of Science ®Google Scholar
• Prébet T, Gore SD, Esterni B et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J. Clin. Oncol. 29(24), 3322–3327 (2011).
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Kohrt HE, Gallegos L et al. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia 26(5), 893–901 (2012).
   PubMed Web of Science ®Google Scholar
• Adès L, Boehrer S, Prebet T et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a Phase 2 study. Blood 113(17), 3947–3952 (2009).
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Gundacker H, Lancet J et al. A Phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood 118(3), 523–528 (2011).
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Uy GL, Trinkaus K et al. A Phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood 117(6), 1828–1833 (2011).
   PubMed Web of Science ®Google Scholar
• Sekeres MA, List AF, Cuthbertson D et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J. Clin. Oncol. 28(13), 2253–2258 (2010).
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Tiu RV, Komrokji R et al. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood 120(25), 4945–4951 (2012).
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Braulke F, Kündgen A et al. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a Phase I study. Leukemia doi:10.1038/leu.2013.26 (2013) (Epub ahead of print).
   Google Scholar
• Sekeres MA, O’Keefe C, List AF et al. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. Am. J. Hematol. 86(1), 102–103 (2011).
   PubMed Web of Science ®Google Scholar
• Komrokji RS, List AF. Role of lenalidomide in the treatment of myelodysplastic syndromes. Semin. Oncol. 38(5), 648–657 (2011).
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson KE, Stojanov P et al. Detection of recurrent mutations by pooled targeted next-generation sequencing in MDS patients prior to treatment with hypomethylating agents or stem cell transplantation. Presented at: 54th Meeting of the American Society of Hematology. Atlanta, GA, USA, 6–11 December 2012.
   Google Scholar